Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: a randomized, prospective, controlled clinical trial in female smokers.
article
OA: closed
CC0
⤵ 13 in-corpus citations
AI-generated summary
This trial found the levonorgestrel-releasing intrauterine system to be superior to oral or intramuscular medroxyprogesterone acetate in improving blood loss and hemoglobin levels for perimenopausal menorrhagia.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
OBJECTIVE: To compare the efficacy of three progestin regimens in perimenopausal menorrhagia. DESIGN: One hundred thirty-two women with menorrhagia were included in this prospective, randomized, comparative trial. Women were randomized to three groups of 44 in each, either to get a single shot of depot medroxyprogesterone acetate, intramuscularly (Group 1), or medroxyprogesterone acetate in a daily dose of 5 mg orally (Group 2), or the levonorgestrel releasing intrauterine system (LNG-IUS) (Group 3). The Mann-Whitney U-test was applied to compare independent groups. RESULTS: Pictorial blood loss assessment chart (PBAC) score, the duration of bleeding and mean hemoglobin level were improved in all groups. Comparing the groups we noted that for the PBAC, there was no statistically significant difference between groups 1 and 2, while group 3 was superior to both groups 1 and 2 (p < 0.05 and p < 0.05, respectively). Mean duration of menstruation showed no differences among the groups. Hemoglobin levels were no statistically significant differences between groups 1 and 2, while group 3 was superior to both groups 1 and 2 (p < 0.05 and p < 0.05, respectively). CONCLUSION: The efficacies of oral and intramuscular medroxyprogesterone acetate in the treatment of menorrhagia were comparable each other, however, the efficacy of LNG-IUS was superior to both.
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
Cited by (13)
- Variation of outcome reporting in studies of interventions for heavy menstrual bleeding: a systematic review 2022
- Bénéfices non contraceptifs des contraceptions. RPC Contraception CNGOF 2018
- A randomised controlled trial of the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia: the ECLIPSE trial 2015
- Medical Management of Heavy Menstrual Bleeding 2015
- Abnormal bleeding in your female patient? Consider a progestin IUD Abnormal bleeding is common in women of childbearing age. For some, insertion of a levonorgestrel-releasing IUD—easily done in a family practice setting—may be all the treatment they need. 2014
- Levonorgestrel-Releasing Intrauterine System versus Medical Therapy for Menorrhagia: A Systematic Review and Meta-Analysis 2014
- Review Article Levonorgestrel Intrauterine System Mirena: An Update 2014
- Nonsurgical Management of Heavy Menstrual Bleeding 2013
- Hormonal and Intrauterine Contraception for Women Aged 40 Years and Older 2013
- Use of combined oral contraceptives for the management of heavy menstrual bleeding 2011
- The efficacy of the levonorgestrel-releasing intrauterine system in perimenopausal women with menorrhagia or dysmenorrhea 2011
- Dysfunctional uterine bleeding: from adolescence to menopause 2010
- Levonorgestrel Intrauterine System Mirena: An Update 1970
Source provenance
- openalex
- last seen: 2026-05-10T10:49:11.780917+00:00
License: CC0
· commercial use OK